News Releases

Chronic kidney disease is most common in people 65 years and older. NLRP3 inflammasomes signaling in the kidneys’ filtration system (“glomerular podocytes”) occurs as early as middle age, leading to scarring, podocyte loss, and impaired function, which may be a critical contributor to a lower
Oct 18, 2023
This review paper summarizes numerous research studies that address the role of kidney cholesterol and lipid accumulation in the development and progression of chronic kidney disease (CKD). ZyVersa’s Cholesterol Efflux Mediator ™  VAR 200 is in development to reduce renal cholesterol and lipid
Oct 11, 2023
The paper, published in Pharmaceuticals , demonstrates that pyrin inflammasome-mediated inflammation induced by traumatic brain injury (TBI) contributes to cardiovascular co-morbidities through systemic release of proinflammatory mediators that activate AIM2 inflammasomes in the heart leading to
Oct 04, 2023
Patients with chronic kidney disease (“CKD”) exhibit chronic systemic inflammation characterized by increased circulating levels of IL-1β, IL-6, and CRP. This study demonstrated that CKD-induced IL-1β activates NLRP3 inflammasomes in the heart’s atria to trigger inflammation promoting the onset and
Sep 22, 2023
Activation of multiple inflammasome pathways contributes to pathological inflammation in neurodegenerative (“CNS”) diseases, such as amyotrophic lateral sclerosis (“ALS”) This study showed that NLRP3 inhibition alone was inadequate to address CNS inflammation in a mouse model of ALS ZyVersa is
Sep 12, 2023
Displaying 31 - 40 of 89